These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8664132)

  • 61. Detection of DNA adducts in the white blood cells of B6C3F1 mice treated with benzene.
    Lévay G; Pathak DN; Bodell WJ
    Carcinogenesis; 1996 Jan; 17(1):151-3. PubMed ID: 8565125
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
    Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.
    van de Vaart PJ; Belderbos J; de Jong D; Sneeuw KC; Majoor D; Bartelink H; Begg AC
    Int J Cancer; 2000 Mar; 89(2):160-6. PubMed ID: 10754494
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.
    Dabholkar M; Bradshaw L; Parker RJ; Gill I; Bostick-Bruton F; Muggia FM; Reed E
    Environ Health Perspect; 1992 Nov; 98():53-9. PubMed ID: 1486863
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure.
    Giurgiovich AJ; Diwan BA; Lee KB; Anderson LM; Rice JM; Poirier MC
    Carcinogenesis; 1996 Aug; 17(8):1665-9. PubMed ID: 8761423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
    Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.
    Kloft C; Eickhoff C; Schulze-Forster K; Maurer HR; Schunack W; Jaehde U
    Pharm Res; 1999 Mar; 16(3):470-3. PubMed ID: 10213383
    [No Abstract]   [Full Text] [Related]  

  • 70. Interaction of cisplatin with other cytotoxics and non-steroidal anti-inflammatory drugs.
    Cosolo W; Schwarz MA; Christophidis N; Zalcberg JR
    Anticancer Drugs; 1991 Apr; 2(2):169-74. PubMed ID: 1958861
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modulation of plasma cyst(e)ine by cisplatin.
    Wung WE; Howell SB
    Eur J Cancer Clin Oncol; 1983 Jul; 19(7):915-8. PubMed ID: 6576906
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinical pharmacology of anti-cancer agents designed for malignant cancers].
    Sasaki Y
    Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1841-5. PubMed ID: 19891100
    [No Abstract]   [Full Text] [Related]  

  • 73. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
    de Jong LAW; Lambert M; van Erp NP; de Vries L; Chatelut E; Ottevanger PB
    Cancer Chemother Pharmacol; 2023 Mar; 91(3):247-256. PubMed ID: 36892677
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors.
    Aguiar Zdovc J; Vaupotič M; Marolt G; Knez L; Režonja Kukec R; Čufer T; Vovk T; Grabnar I
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):301-313. PubMed ID: 35986742
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.
    Murakami T; Kikuchi E; Ide H; Umezawa Y; Takahashi T; Izawa M; Hakozaki K; Shigeta K; Ogihara K; Kobayashi H; Kanai K; Maeda T; Yoshimine S; Mizuno R; Nishimoto K; Oya M
    BJUI Compass; 2021 Sep; 2(5):322-330. PubMed ID: 35474877
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.
    Boosman RJ; Burgers JA; Smit EF; Steeghs N; van der Wekken AJ; Beijnen JH; Huitema ADR; Ter Heine R
    Drugs; 2022 Jan; 82(1):15-32. PubMed ID: 34894338
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis.
    Goto Y; Kanao K; Matsumoto K; Kobayashi I; Kajikawa K; Onishi M
    Int Cancer Conf J; 2021 Jul; 10(3):212-216. PubMed ID: 34221834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.
    Zimmermann M; Li T; Semrad TJ; Wu CY; Yu A; Cimino G; Malfatti M; Haack K; Turteltaub KW; Pan CX; Cho M; Kim EJ; Henderson PT
    Mol Cancer Ther; 2020 Apr; 19(4):1070-1079. PubMed ID: 32029633
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report.
    Wang D; Li X; Xu L; Fang W; Cai X; Wang Y; Wang J; Wang Y; Zhao F; Gu Y
    Medicine (Baltimore); 2019 Nov; 98(44):e17462. PubMed ID: 31689749
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
    Rao D; Mallick AB; Augustine T; Daroqui C; Jiffry J; Merla A; Chaudhary I; Seetharam R; Sood A; Gajavelli S; Aparo S; Rajdev L; Kaubisch A; Chuy J; Negassa A; Mariadason JM; Maitra R; Goel S
    Oncotarget; 2019 Sep; 10(53):5510-5522. PubMed ID: 31565185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.